Continuous CSF drainage in AD: Results of a double-blind, randomized, placebo-controlled study

Neurology

Volumn 71, Issue 3, 2008, Pages 202-209

  Silverberg, G D ^a,g   Mayo, M ^b   Saul, T ^c   Fellmann, J ^d   Carvalho, J ^e   McGuire, D ^f  

^a BROWN UNIVERSITY   (United States)

^b AFFYMAX RESEARCH INSTITUTE   (United States)

^c Saul Consulting   (United States)

^d Acologix Inc   (United States)

^e Genitope Corporation   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIBIOTIC AGENT; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ANTIBIOTIC THERAPY; ARTICLE; BRAIN BLOOD FLOW; BRAIN VENTRICLE PERITONEUM SHUNT; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID DRAINAGE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE INFECTION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT SAFETY; PLACEBO EFFECT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID SHUNTING; COMPARATIVE STUDY; HOSPITALIZATION; INSTRUMENTATION; METHODOLOGY; PATHOLOGY; PROSPECTIVE STUDY; TIME; WOUND DRAINAGE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID SHUNTS; DOUBLE-BLIND METHOD; DRAINAGE; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 48449100885     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000316197.04157.6f     Document Type: Article

References (40)

1. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease: hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000;924:17-25.
2. Rubenstein E. Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged. Lancet 1998;351:283-285.
3. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2003;2:506-511.
4. Alzheimer's Association Fact Sheet. Statistics About Alzheimer's Disease. Alzheimer's Disease and Associated Disorder, Inc. July (2002). Available at: http://www.alz.org/ ResourceCenter/FactSheets/FSAlzheimerStats.pdf
5. Anttila T, Helkala EL, Kivipelto M, et al. Midlife income, occupation, APOE status, and dementia: a populationbased study. Neurology 2002;59:887-893.
6. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. Aging renders the brain vulnerable to amyloid betaprotein neurotoxicity. Nat Med 1998;4:827-831.
7. Preston JE. Aging choroid plexus-cerebrospinal fluid system. Microsc Res Tech 2001;52:31-37.
8. Mucke L, Roberson E, Scearce-Levie K, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316: 750-754.
9. 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-1499.
10. Davson H, Oldendorf WH. Symposium on membrane transport: transport in the central nervous system. Proc R Soc Med 1967;60:326-329.
11. Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-150.
12. Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 2001;57:1763-1766.
13. Zlokovic B. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28:202-208.
14. Deane R, Yan SD, Kumar R, et al. Rage mediates amyloid-jS peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-913.
15. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1 and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (Berl) 2006;112:405-415.
16. Silverberg GD, Levinthal E, Sullivan EV, et al. Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology 2002;59:1139-1145.
17. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellack R, Karasu B, eds. Geriatric Psychiatry. New York: Grune and Stratton, 1976:77-121.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price M, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34: 939-944.
19. Silverberg GD, Mayo M, Saul T, Fellmann J, McGuire D. Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease. CSF Research 2006;3:7.
20. HolodnyAI, Waxman R, George AE, Rusinek H, Kalnin AJ, de Leon M. MR differential diagnosis of normal-pressure hydrocephalus and Alzheimer disease: significance of perihippocampal fissures. Am J Neuroradiol 1998;19: 813-819.
21. Reisberg B, Ferris SH, de Leon MJ, Crook J. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
22. Standish TI, Molloy DW, Bedard M, Layne EC, Murray EA, Strang D. Improved reliability of the Standardised Alzheimer's disease Assessment Scale (SADAS) compared with the Alzheimer's disease Assessment Scale (ADAS). J Am Geriatr Soc 1996;44:712-716.
23. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer's Dis Assoc Disord 1997;11(suppl 2):533-539.
24. Nelson HE, Wilison JR. The Revised National Adult Reading Test-Test Manual. Windsor, Berks: NFERNELSON, 1991.
25. Fama R, Sullivan FV, Shear PK, et al. Selective cortical and hippocampal volume correlates of Mattis Dementia Rating Scale in Alzheimer's disease. Arch Neurol 1997;54:719-728.
26. Smith GE, Ivnik RJ, Malec JF, Kokmen E, Tangelos E, Petersen RC. Psychometric properties of the Mattis Dementia Rating Scale. Assessment 1994;1:123-132.
27. Andreasen N, Hesse C, Davidson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56: 673-680.
28. Blennow K, Zetterberg H, Minton L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007;419:18-22.
29. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40 and A beta1- 42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
30. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI. Cerebrospinal fluid production is reduced in healthy aging. Neurology 1990;40:500-503.
31. Klinge PM, Samii A, Niesken S, Brinker T, Silverberg GD. Brain amyloid accumulation in aged rats with kaolininduced hydrocephalus NeuroReport 2006;17:657-660.
32. Silverberg GD, Huhn S, Jaffee RA, et al. Downregulation of cerebrospinal fluid production in patients with chronic hydrocephalus. J Neurosurg 2002;97:1271-1275.
33. Bateman RJ, Munsell LY, Morris JC, Swarm R, Varasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-861.
34. Bell RD, Sagare AP, Friednab AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2006;27:909-918.
35. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001;310:173-186.
36. Giedraitis V, Sundelöf J, Irizarry MC, et al. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 2007; 427:127-131.
37. Galasko DR, Gould RL, Abramson IS, Salmon DP. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Statist Med 2000;19:1421-1432.
38. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN 1792) in patients with AD in an interrupted study. Neurology 2005;64:1553-1562.
39. Blount JP, Campbell JA, Haines SJ. Complications in ventricular cerebrospinal fluid shunting. Neurosurg Clin North Am 1993;4:633-656.
40. Noetzel MJ, Baker RP. Shunt fluid examination: risks and benefits in the evaluation of shunt malfunction and infection. J Neurosurg 1984;61:328-332.